Compare BMBL & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMBL | FULC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.6M | 467.8M |
| IPO Year | 2021 | 2019 |
| Metric | BMBL | FULC |
|---|---|---|
| Price | $2.84 | $3.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $4.46 | ★ $16.38 |
| AVG Volume (30 Days) | ★ 2.9M | 2.4M |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $965,658,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.61 | $2.83 |
| 52 Week High | $8.63 | $15.74 |
| Indicator | BMBL | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 25.82 |
| Support Level | $2.68 | N/A |
| Resistance Level | $3.85 | $8.18 |
| Average True Range (ATR) | 0.17 | 0.35 |
| MACD | -0.02 | -0.34 |
| Stochastic Oscillator | 5.50 | 18.40 |
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.